Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 … Next › Last »

Prevision Policy Clips | Novavax COVID Vaccine Delay: Commissioner Makary Confirms Demand For Clinical Trial

April 28, 2025

Prevision Policy Clips | Merck, Bristol Reassure Investors That FDA Reviews Are Proceeding On Time For Now

April 25, 2025

340B Contract Pharmacy Restrictions’ Impact Is Waning, Manufacturers Tell Sen. Cassidy; Report Quantifies Effect On Lilly, J&J, And Amgen, Fuels Cassidy’s Call For Reforms

April 24, 2025

FDA Expands Catalogue Of Rare Disease Case Studies: New Examples Look At Surrogate Endpoints (Qalsody, Nexviazyme, Livdelzi), Externally Controlled Trials (Amvuttra) And Novel COAs (Bylvay)

April 24, 2025

Making “Cost-Effective” Drugs “Affordable”: ICER Obesity White Paper Offers Options To Expand Access To GLP-1s For Insurers, Policymakers To Consider

April 24, 2025

Prevision Policy Clips | FDA Rare Disease Case Studies Include Biogen’s Qalsody And Alnylam’s Amvuttra

April 24, 2025

FDA Layoff Impact On Review Activities Detailed By CDER In Letter To Vanda; Message In Context Of Dispute May Have Broader Audience In Mind

April 23, 2025

Prevision Policy Clips | Novavax COVID BLA Review: Company Asked For Post-Marketing Commitment “To Generate Additional Clinical Data”

April 23, 2025

MASH Histology Assessment AI-Assisted Tool Approved In Europe; Biomarker’s Qualification Is Ongoing At FDA

April 22, 2025

Nanoscope Retinitis Pigmentosa Treatment Would Benefit From Value-Based Contracting, ICER Says; Panel Revisits Ophthalmic Gene Therapy Seven Years After Luxturna

April 22, 2025

Prevision Policy Clips | OCE Loses Two More: Associate Director For Biomarkers And Precision Oncology Reena Philip

April 22, 2025

Conditional Approval Pathway For Ultra-Rare Conditions Based On “Plausible Mechanism” Floated By FDA Commissioner Makary

April 21, 2025

Prevision Policy Clips | CMS Center For Medicare Director Is John Brooks

April 21, 2025

FDA Advisory Committee Industry Reps Sacrificed To “Radical Transparency”; Commissioner Makary Defends FDA Cuts In On-Line Interview

April 18, 2025

Prevision Policy Clips | No More Industry Reps: FDA Advisory Committees Will No Longer Have Company Executives

April 18, 2025

CAR-T Differences Debated Again In CMS Discussion Of NTAP Applicants For FY 2026; 13 Drugs Seek New Technology Add-On Payments

April 17, 2025

Prevision Policy Clips | HHS Draft Budget Proposal Protects User Fee “Triggers,” But Cuts FDA Appropriations

April 17, 2025

Improving The IRA: Trump Drug Pricing Executive Order Has Many Positives For Pharma, Though HHS Demo Is Threat To Monitor; Policy Menu Largely Unchanged From 2017

April 16, 2025

Prevision Policy Clips | Improving The IRA: Trump Drug Pricing Executive Order Includes Call To End “Pill Penalty”

April 16, 2025

Prevision Policy Clips | FTC Looking To Roll Back “Anti-Competitive Regulations”

April 15, 2025

Saving Part D: MedPAC Debates Ways To Make Stand-Alone Plans More Viable; Warns That Future Of Traditional Medicare May Be At Stake

April 14, 2025

Fixing Biosimilars: Stelara Will Be Test Of Price Negotiation Impact; FDA Cuts May Have Significant Adverse Effect At Tough Time For Sector

April 14, 2025

“A Slow Moving Catastrophe”: FDA Layoffs Will Result In Less Guidance And Less Flexibility, Ex-Leaders Suggest; Cell/Gene Therapy Could Be A Bright Spot

April 14, 2025

Prevision Policy Clips | Digital Health Technologies In Clinical Trials: FDA Viewpoint Posted In JAMA

April 14, 2025

FDA “Five-Office” Reorg Proposal Criticized By Former Senior Officials; Regulatory Work Is Too Specialized For A “Big Team Of Generalists”

April 11, 2025
1 2 3 4 5 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2025 Prevision Policy. All Rights Reserved. Privacy Policy